Overview

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

Status:
Recruiting

Trial end date:
2022-08-30

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate the efficacy, safety and tolerability of pyrotinib combination with CDK4/6 Inhibitor SHR6390 in advanced HER2-Positive breast cancer patients who prior trastuzumab-treated.

Phase:

Phase 2

Details

Lead Sponsor:

Jinming Yu

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Capecitabine
Letrozole
Trastuzumab